Provenge Data Not Supportive Of Off-Label Uses, MEDCAC Finds

The existing clinical data on Dendreon's prostate cancer vaccine Provenge cannot be "generalizable" to off label uses, most members of the Medicare Evidence Development and Coverage Advisory Committee agreed at a Nov. 17 meeting.